Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Igor Stukalin"'
Autor:
Annalise G. Abbott, Daniel E. Meyers, Golpira Elmi-Assadzadeh, Igor Stukalin, Alessandro Marro, Shannon K. T. Puloski, Don G. Morris, Winson Y. Cheung, Michael J. Monument
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose of this study was to compare
Externí odkaz:
https://doaj.org/article/8e3e67f0686b45c6b44687246b392205
Autor:
Mehul Gupta, Igor Stukalin, Daniel E. Meyers, Daniel Y. C. Heng, Jose Monzon, Tina Cheng, Vishal Navani
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe association between objective imaging response and first line immune checkpoint inhibitor (ICI) therapy regimes in advanced melanoma remains uncharacterized in routine practice.MethodsWe conducted a multi-center retrospective cohort ana
Externí odkaz:
https://doaj.org/article/3a7a0cf228e44e9382aeb927341c82e3
Autor:
Chloe Ahryung Lim, Sunita Ghosh, Hali Morrison, Daniel Meyers, Igor Stukalin, Marc Kerba, Desiree Hao, Aliyah Pabani
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10396-10407 (2023)
The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical complications. This study aim
Externí odkaz:
https://doaj.org/article/effea2a6f0be42d7b9b6ef97fd2e41c6
Autor:
Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8936-8947 (2023)
Background: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. Methods: A retrospective, multi-center, provincial cohort da
Externí odkaz:
https://doaj.org/article/d3356bccbd954bebb8c1372aca614954
Autor:
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, Tina Cheng
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7695-7704 (2022)
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elus
Externí odkaz:
https://doaj.org/article/1f5f9e1739c3404695cccba5ce955721
Autor:
Daniel E. Meyers, MD, MSc, Meghann Pasternak, MD, MSc, Samantha Dolter, MD, Heidi A.I. Grosjean, MD, Chloe A. Lim, MD, Igor Stukalin, MD, Siddhartha Goutam, MD, Vishal Navani, M.B.B.S., MRCP, Daniel Y.C. Heng, MD, MPH, Winson Y. Cheung, MD, PhD, Don G. Morris, MD, PhD, Aliyah Pabani, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100482- (2023)
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance stat
Externí odkaz:
https://doaj.org/article/60af4c1049ba410eb0ed27eb16724e8a
Autor:
Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4213-4222 (2021)
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice
Externí odkaz:
https://doaj.org/article/ef1a3db40d2d4a92a300be45448be0e8
Autor:
Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2618-2626 (2021)
Abstract Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to
Externí odkaz:
https://doaj.org/article/912792318bd545cba1e0cd7fc036db6d
Autor:
Domen Ribnikar, Igor Stukalin, Philippe L. Bedard, Robert J. Hamilton, Michael Jewett, Padraig Warde, Peter Chung, Lynn Anson-Cartwright, Arnoud J. Templeton, Eitan Amir, Aaron R. Hansen, Daniel Y. C. Heng, Jeremy Lewin
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 107-114 (2020)
We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatmen
Externí odkaz:
https://doaj.org/article/74268072d0d94d00b13168f8a9e2b0f1
Publikováno v:
Urology Case Reports, Vol 26, Iss , Pp - (2019)
Primary urethral carcinomas are rare tumors and their incidence increases with age. Urothelial carcinoma is the most common histologic type of primary urethral carcinoma, followed by squamous cell carcinoma and adenocarcinoma. Adenocarcinoma arising
Externí odkaz:
https://doaj.org/article/1ee3da91e1e84055a896e46e23794320